

Information for Connecticut Prescribers of Prescription Drugs

Foundayo™ (orforglipron)

- Connecticut Public Act No. 23-171 requires “pharmaceutical representatives” (as defined in the Act) provide certain information to prescribers and pharmacists. The information in this disclosure is being provided pursuant to this Act.
- Lilly USA LLC's Wholesale Acquisition Cost (WAC) is the listed price to the distribution channel not including prompt pay, service or administrative fees, stocking or distribution allowances, or any discounts, rebates, or chargebacks provided by Lilly USA to any entity.

Product:

BRAND NAME	GENERIC NAME	STRENGTH	DOSAGE FORM	PACK SIZE	NDC	WHOLESALE ACQUISITION COST ¹
Foundayo™	orforglipron	0.8 mg	Tablet	30	0002-4178-31	\$649.00
		2.5 mg	Tablet	30	0002-4503-31	\$649.00
		5.5 mg	Tablet	30	0002-4794-31	\$649.00
		9 mg	Tablet	30	0002-4803-31	\$649.00
		14.5 mg	Tablet	30	0002-4839-31	\$649.00
		17.2 mg	Tablet	30	0002-4953-31	\$649.00

In adult patients with obesity or overweight, a reduction in body weight was observed with FOUNDAYO™ irrespective of race or ethnicity.²

Please see accompanying [Prescribing Information](#) and [Medication Guide](#) Including Boxed Warning.

Foundayo™ is a trademark of Eli Lilly and Company.

¹ Source: AnalySource®. Accessed on 04/02/2026. WAC reprinted with permission by First Databank Inc. All rights reserved. © 2026. <http://www.fdbhealth.com/policies/drug-pricing-policy/>.

² US Foundayo Prescribing Information.